vs

Side-by-side financial comparison of LXP Industrial Trust (LXP) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

LXP Industrial Trust is the larger business by last-quarter revenue ($86.7M vs $44.6M, roughly 1.9× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). LXP Industrial Trust runs the higher net margin — 33.2% vs -90.4%, a 123.6% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs -14.0%). Over the past eight quarters, PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s revenue compounded faster (7.3% CAGR vs 0.3%).

LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

LXP vs PACB — Head-to-Head

Bigger by revenue
LXP
LXP
1.9× larger
LXP
$86.7M
$44.6M
PACB
Growing faster (revenue YoY)
PACB
PACB
+27.8% gap
PACB
13.8%
-14.0%
LXP
Higher net margin
LXP
LXP
123.6% more per $
LXP
33.2%
-90.4%
PACB
Faster 2-yr revenue CAGR
PACB
PACB
Annualised
PACB
7.3%
0.3%
LXP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LXP
LXP
PACB
PACB
Revenue
$86.7M
$44.6M
Net Profit
$28.8M
$-40.4M
Gross Margin
81.5%
37.1%
Operating Margin
34.6%
-92.3%
Net Margin
33.2%
-90.4%
Revenue YoY
-14.0%
13.8%
Net Profit YoY
-1802.7%
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LXP
LXP
PACB
PACB
Q4 25
$86.7M
$44.6M
Q3 25
$86.9M
$38.4M
Q2 25
$87.7M
$39.8M
Q1 25
$88.9M
$37.2M
Q4 24
$100.9M
$39.2M
Q3 24
$85.6M
$40.0M
Q2 24
$85.8M
$36.0M
Q1 24
$86.3M
$38.8M
Net Profit
LXP
LXP
PACB
PACB
Q4 25
$28.8M
$-40.4M
Q3 25
$36.3M
$-38.0M
Q2 25
$29.1M
$-41.9M
Q1 25
$19.0M
$-426.1M
Q4 24
$2.4M
Q3 24
$6.3M
$-60.7M
Q2 24
$5.4M
$-173.3M
Q1 24
$-269.0K
$-78.2M
Gross Margin
LXP
LXP
PACB
PACB
Q4 25
81.5%
37.1%
Q3 25
82.3%
41.4%
Q2 25
81.9%
36.9%
Q1 25
80.7%
-3.7%
Q4 24
85.3%
25.6%
Q3 24
82.5%
25.0%
Q2 24
82.0%
16.5%
Q1 24
82.4%
29.1%
Operating Margin
LXP
LXP
PACB
PACB
Q4 25
34.6%
-92.3%
Q3 25
50.4%
-101.1%
Q2 25
33.7%
-112.8%
Q1 25
21.8%
-1154.5%
Q4 24
-390.1%
Q3 24
7.9%
-160.3%
Q2 24
6.9%
-488.3%
Q1 24
1.0%
-209.6%
Net Margin
LXP
LXP
PACB
PACB
Q4 25
33.2%
-90.4%
Q3 25
41.7%
-98.9%
Q2 25
33.2%
-105.4%
Q1 25
21.4%
-1146.8%
Q4 24
6.0%
Q3 24
7.4%
-151.9%
Q2 24
6.3%
-481.3%
Q1 24
-0.3%
-201.4%
EPS (diluted)
LXP
LXP
PACB
PACB
Q4 25
$-0.11
Q3 25
$0.12
$-0.13
Q2 25
$0.09
$-0.14
Q1 25
$0.06
$-1.44
Q4 24
$-0.44
Q3 24
$0.02
$-0.22
Q2 24
$0.01
$-0.64
Q1 24
$-0.01
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LXP
LXP
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$170.4M
$279.5M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$2.0B
$5.3M
Total Assets
$3.5B
$784.1M
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LXP
LXP
PACB
PACB
Q4 25
$170.4M
$279.5M
Q3 25
$229.7M
$298.7M
Q2 25
$71.0M
$314.7M
Q1 25
$70.9M
$343.1M
Q4 24
$101.8M
$389.9M
Q3 24
$55.0M
$471.1M
Q2 24
$48.7M
$509.8M
Q1 24
$293.8M
$561.9M
Total Debt
LXP
LXP
PACB
PACB
Q4 25
$1.4B
Q3 25
$1.5B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.6B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
LXP
LXP
PACB
PACB
Q4 25
$2.0B
$5.3M
Q3 25
$2.1B
$36.1M
Q2 25
$2.1B
$61.5M
Q1 25
$2.1B
$91.6M
Q4 24
$2.1B
$506.6M
Q3 24
$2.1B
$453.1M
Q2 24
$2.1B
$492.7M
Q1 24
$2.2B
$649.0M
Total Assets
LXP
LXP
PACB
PACB
Q4 25
$3.5B
$784.1M
Q3 25
$3.7B
$803.2M
Q2 25
$3.7B
$825.5M
Q1 25
$3.8B
$860.8M
Q4 24
$3.8B
$1.3B
Q3 24
$3.9B
$1.5B
Q2 24
$3.9B
$1.5B
Q1 24
$4.2B
$1.7B
Debt / Equity
LXP
LXP
PACB
PACB
Q4 25
0.66×
Q3 25
0.72×
Q2 25
0.72×
Q1 25
0.73×
Q4 24
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LXP
LXP
PACB
PACB
Operating Cash FlowLast quarter
$188.7M
$-19.1M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-44.6%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
6.56×
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LXP
LXP
PACB
PACB
Q4 25
$188.7M
$-19.1M
Q3 25
$63.5M
$-18.7M
Q2 25
$44.3M
$-29.4M
Q1 25
$39.0M
$-44.1M
Q4 24
$211.2M
$-30.6M
Q3 24
$64.6M
$-45.5M
Q2 24
$38.5M
$-54.3M
Q1 24
$38.9M
$-75.7M
Free Cash Flow
LXP
LXP
PACB
PACB
Q4 25
$-19.9M
Q3 25
$-18.8M
Q2 25
$-29.9M
Q1 25
$-45.4M
Q4 24
$-32.3M
Q3 24
$-46.3M
Q2 24
$-55.7M
Q1 24
$-79.6M
FCF Margin
LXP
LXP
PACB
PACB
Q4 25
-44.6%
Q3 25
-48.9%
Q2 25
-75.3%
Q1 25
-122.3%
Q4 24
-82.3%
Q3 24
-115.7%
Q2 24
-154.8%
Q1 24
-205.0%
Capex Intensity
LXP
LXP
PACB
PACB
Q4 25
1.9%
Q3 25
0.2%
Q2 25
1.4%
Q1 25
3.7%
Q4 24
4.1%
Q3 24
2.0%
Q2 24
4.1%
Q1 24
10.0%
Cash Conversion
LXP
LXP
PACB
PACB
Q4 25
6.56×
Q3 25
1.75×
Q2 25
1.52×
Q1 25
2.05×
Q4 24
-12.93×
Q3 24
10.18×
Q2 24
7.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LXP
LXP

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons